CN116396218A - Synthesis method of benzazepine compound - Google Patents
Synthesis method of benzazepine compound Download PDFInfo
- Publication number
- CN116396218A CN116396218A CN202310148318.3A CN202310148318A CN116396218A CN 116396218 A CN116396218 A CN 116396218A CN 202310148318 A CN202310148318 A CN 202310148318A CN 116396218 A CN116396218 A CN 116396218A
- Authority
- CN
- China
- Prior art keywords
- synthesizing
- reaction
- aryl
- compound according
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 benzazepine compound Chemical class 0.000 title claims abstract description 54
- 238000001308 synthesis method Methods 0.000 title claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 25
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 11
- 230000003213 activating effect Effects 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000011065 in-situ storage Methods 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 54
- 125000003118 aryl group Chemical group 0.000 claims description 20
- TXVLFCLSVCYBIV-UHFFFAOYSA-M dimethyl(methylsulfanyl)sulfanium;trifluoromethanesulfonate Chemical compound CS[S+](C)C.[O-]S(=O)(=O)C(F)(F)F TXVLFCLSVCYBIV-UHFFFAOYSA-M 0.000 claims description 20
- 238000004440 column chromatography Methods 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 20
- 150000008038 benzoazepines Chemical class 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 4
- 150000001408 amides Chemical class 0.000 abstract description 3
- 239000003054 catalyst Substances 0.000 abstract description 3
- 125000000524 functional group Chemical group 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract description 3
- 239000012190 activator Substances 0.000 abstract description 2
- 238000007363 ring formation reaction Methods 0.000 abstract description 2
- 150000003463 sulfur Chemical class 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000012299 nitrogen atmosphere Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- QAYPFHIZJSDUSF-UHFFFAOYSA-N azepin-3-one Chemical compound O=C1C=CC=CN=C1 QAYPFHIZJSDUSF-UHFFFAOYSA-N 0.000 description 32
- 239000000047 product Substances 0.000 description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 13
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 12
- 238000002390 rotary evaporation Methods 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 229910001873 dinitrogen Inorganic materials 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- DOZZSWAOPDYVLH-UHFFFAOYSA-N 2-phenylpropanamide Chemical compound NC(=O)C(C)C1=CC=CC=C1 DOZZSWAOPDYVLH-UHFFFAOYSA-N 0.000 description 1
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000005865 alkene metathesis reaction Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- LXAWHMFHGHNIHC-UHFFFAOYSA-N sulfanyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OS LXAWHMFHGHNIHC-UHFFFAOYSA-N 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
The invention discloses a synthesis method of a benzoazepine compound; in the method, sulfur salt generated in situ by methyl triflate and dimethyl sulfide is used as an activating agent to carry out cyclization reaction with N, N-dibenzyl-3-phenylpropyl amide compounds at 80 ℃ in nitrogen atmosphere to generate benzoazepine compounds; wherein methyl triflate and dimethyl sulfide are activator precursors; amide compounds include aryl amides, alkyl amides, heterocyclic amides, and amides having an asymmetric functional group attached to N; the method is a novel method for synthesizing the benzoazepine compound, has no participation of catalyst and additive, has the advantages of simple and easily obtained required raw materials, mild reaction conditions, simple operation, high reaction yield, excellent compatibility of substrate functional groups and higher application value.
Description
Technical Field
The invention relates to the technical field of synthesis of organic intermediates, in particular to a synthesis method of a benzazepine compound.
Background
The benzoazepine compound is an important heterocyclic organic compound, wherein the quantity of the benzoazepine seven-membered ring compound is not as much as that of the aza five-membered ring and the aza six-membered ring in the natural world, most of the benzoazepine compound exists in the form of alkaloid, has excellent biological activity and medicinal value, and a plurality of benzoazepine compounds are clinically used as medicines for treating central nervous system at present, such as antidepressant Ansufenib, antipsychotic olanzapine, antiepileptic medicine chlordiazepoxide and the like. Therefore, the development of a novel synthesis method of the benzoazepine compound has important theoretical significance and practical value.
At present, the method for synthesizing the benzazepine compound comprises the following steps:
the method comprises the following steps: starting from the phenylpropionamide, reacting with paraformaldehyde through a Pictet-Spengler reaction, and finally reducing to obtain the benzazepine compound.
The limitation of this method is: the paraformaldehyde is used as a raw material for preparation, so that the paraformaldehyde has great harm to human bodies and the environment, and the substance has explosion danger when exposed to fire, high heat or contact with an oxidant, so that the paraformaldehyde is not beneficial to industrial production.
The second method is as follows: ring-expanding reaction of tetralone and hydrazoic acid to obtain lactam, and reduction to obtain benzazepine compound.
The method has the following defects: tetralone and sodium azide are used as starting materials, the tetralone and air are easy to form an explosive mixture, and the sodium azide is directly exploded, so that great potential safety hazards exist.
And a third method: metal catalyzed olefin metathesis reactions are used to prepare benzoazepines.
The method has the following defects: the noble metal catalyzed olefin double decomposition reaction is adopted, the catalyst is high in price, the application range of the substrate is limited to a certain extent, and the industrial production cost is high.
In summary, although the current synthesis methods of benzoazepine compounds are various, the synthesis strategies still face the problems of harsh reaction conditions, metal participation, high cost, low universality and the like.
Disclosure of Invention
Aiming at the problems, the invention aims to provide a synthesis method of the benzoazepine compound, which is simple and convenient to operate, good in functional group tolerance, high in reaction yield and easy to popularize in industrial production.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: a synthesis method of a benzoazepine compound comprises the following steps:
wherein the activating agent is sulfur salt generated in situ by methyl triflate and dimethyl sulfide;
R 1 and R is 2 Are all substituents selected from C 1 ～C 3 Alkyl or silicon-based, 5-membered heteroaryl groups containing S heteroatoms, C 6 ～C 10 And aryl containing a secondary substituent; the secondary substituent is selected from H, methyl, hydrocarbyloxy, ester, trifluoromethyl, isopropyl, tert-butyl, trimethylsilyl or halogen.
R of the invention 1 Preferably C 6 ～C 10 And aryl containing a secondary substituent; the secondary substituent is selected from H, methyl, hydrocarbyloxy, ester, trifluoromethyl, trimethylsilyl or halogen.
R of the invention 2 Preferably C 6 ～C 10 And aryl containing a secondary substituent; the secondary substituent is selected from H, methyl, trifluoromethyl or halogen.
R of the invention 1 Further preferred are methyl-containing aryl, trifluoromethyl-containing aryl, F-containing aryl or trimethylsilyl groups. Wherein the substituents in the aryl group: methyl, trifluoromethyl and F are all para-substituted.
R of the invention 2 Further preferred aryl, F-containing aryl or trifluoromethyl-containing aryl; wherein the substituents in the aryl group: and the methyl and F are para-position substitution.
The activator of the invention: the molar ratio of the dimethyl (methylthio) sulfonium triflate to the amide compound is 1:1-1.5:1; preferably, the molar ratio of the dimethyl (methylthio) sulfonium triflate to the amide compound is 1.2:1, and when the molar ratio is 1.2:1, the yield of the final product is high.
The reaction solvent of the present invention is preferably acetonitrile, and the molar concentration of the raw material amide compound in the reaction solvent is preferably 0.1mmol/mL. In the invention, a single organic solvent is used as a reaction system, if other needs exist in the system, but from the aspects of reaction efficiency and simplicity of operation, the single organic solvent is preferably used as the reaction system without adding other organic solvents.
The reaction temperature of the invention is 20-90 ℃, preferably 80 ℃; the reaction time is 8-18 h, preferably 12h; the reaction temperature and the reaction time of the invention can be determined by the skilled person according to different reactants and according to actual needs.
After the reaction is completed, the synthesis method does not need extraction, and the refined benzoazepine compound is obtained through column chromatography separation.
The invention has the advantages that: the method takes the simple and easily obtained amide compound as a reaction substrate to carry out cyclization reaction with dimethyl (methylthio) sulfonium triflate (activating agent), and synthesizes the benzoazepine compound simply and efficiently under the nitrogen condition at the reaction temperature of 80 ℃. Compared with other methods for synthesizing the benzoazepine compound, the method has the advantages of mild conditions, easily obtained raw materials, no need of participation of a metal catalyst, low reaction cost and no potential safety hazard, and can be popularized to industrial production.
The invention can be widely applied to the drug synthesis in industry and academia and the total synthesis of natural products, and has higher application value.
Drawings
FIG. 1 is a nuclear magnetic resonance hydrogen spectrum of 2-benzyl-4-methylsulfanyl-5-p-tolyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one described in example 1;
FIG. 2 is a nuclear magnetic resonance spectrum of 2-benzyl-4-methylsulfanyl-5-p-tolyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one described in example 1;
FIG. 3 is a nuclear magnetic resonance spectrum of methyl 4- (2-benzyl-4-methylsulfanyl) -3-oxo-2, 3-dihydro-1H-benzo [ c ] azepin-5-yl) benzoate described in example 7;
FIG. 4 is a nuclear magnetic resonance spectrum of methyl 4- (2-benzyl-4-methylsulfanyl) -3-oxo-2, 3-dihydro-1H-benzo [ c ] azepin-5-yl) benzoate described in example 7;
FIG. 5 is a nuclear magnetic resonance hydrogen spectrum of 2-benzyl-5- (2-chlorophenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one according to example 10;
FIG. 6 is a nuclear magnetic resonance spectrum of 2-benzyl-5- (2-chlorophenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one according to example 10;
FIG. 7 is a nuclear magnetic resonance hydrogen spectrum of 2-isopropyl-4-methylsulfanyl-5-phenyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one described in example 11;
FIG. 8 is a nuclear magnetic resonance spectrum of 2-isopropyl-4-methylsulfanyl-5-phenyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one described in example 11;
FIG. 9 is a nuclear magnetic resonance spectrum of 4- (2-benzyl-4-methylsulfanyl) -3-oxo-2, 3-dihydro-1H-benzo [ c ] azepin-5-yl) benzonitrile according to example 12;
FIG. 10 is a nuclear magnetic resonance spectrum of 4- (2-benzyl-4-methylsulfanyl) -3-oxo-2, 3-dihydro-1H-benzo [ c ] azepin-5-yl) benzonitrile according to example 12;
Detailed Description
The invention is described in further detail below in conjunction with the detailed description and the accompanying drawings;
in the present invention, "amide-based compound" has the meaning commonly understood by those skilled in the art, i.e., contains an amine-based compound directly linked to an acyl group, R 1 Attached to the amide compound by a C.ident.C bond, for example, N-dibenzyl-3- (p-tolyl) propynylamide, N-dibenzyl-3-m-tolylpropyl amide, N-dibenzyl-3- (2-chlorophenyl) propynylamide, N-dibenzyl-3- (thiophen-2-yl) propynylamide and various derivatives thereof.
The starting materials used in the following examples are commercially available, and each reagent is purified, if necessary, by means well known in the art and used.
1 H NMR 13 C NMR was measured using a Bruker Avance 400spectrometer instrument. The test temperature was room temperature, and the solvent was deuterated chloroform (CDCl) 3 ) Selecting reference: 1 H NMR:CDCl 3 7.26ppm; 13 C NMR:CHCl 3 77.0ppm.
Example 1: synthesis of 2-benzyl-4-methylsulfanyl-5-p-tolyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzyl-3- (p-tolyl) propynylamide (101.8 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube dried and repeatedly replaced with nitrogen 3 times at room temperature, and reacted at 80℃for 12 hours. After the reaction is finished, filtering and rotary steaming to obtain a crude product, and further separating and purifying by using column chromatography to obtain 87.5mg of a product with the yield of 76%; the nuclear magnetic hydrogen spectrum is shown in figure 1.
The product 2-benzyl-4-methylsulfanyl-5-p-tolyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.37-7.27 (m, 5H), 7.23-7.11 (m, 6H), 7.06-7.04 (m, 1H), 6.87-6.85 (m, 1H), 5.22 (d, J=14.8 Hz, 1H), 4.54 (d, J=14.8 Hz, 1H), 4.21 (d, J=14.8 Hz, 1H), 3.96 (d, J=14.4 Hz, 1H), 2.40 (s, 3H), 2.35 (s, 3H) 13C NMR (101 MHz, CDCl 3) delta 164.3,141.9,138.8,138.4,137.7,137.0,136.9,135.0,130.9,130.0,129.1,128.8,128.2,127.9,127.90,127.7,126.5,50.2,49.3,21.5,17.6. The nuclear magnetic carbon spectrum is shown in FIG. 2.
Example 2: synthesis of 2-benzyl-5- (4-fluorophenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzyl-3- (4-fluorophenyl) propynylamide (103.1 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 78.3mg of the product in 67% yield.
Product(s)2-benzyl-5- (4-fluorophenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ]]Azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.39-7.29 (m, 5H), 7.23-7.19 (m, 4H), 7.14-7.07 (m, 3H), 6.85-6.83 (m, 1H), 5.22 (d, J=14.8 Hz, 1H), 4.55 (d, J=14.4 Hz, 1H), 4.25 (d, J=14.8 Hz, 1H), 4.00 (d, J=14.8 Hz, 1H), 2.38 (s, 3H) 13C NMR (101 MHz, CDCl 3) delta 164.1,163.8,161.3 (d, J) C-F ＝249.4Hz),140.6,138.5,137.0,136.9(d,J C-F ＝8.8Hz),136.5,136.4(d,J C-F ＝3.4Hz),135.8,132.0,132.0(d,J C-F ＝8.3Hz),130.7,128.8,128.2,128.1,128.0,127.7,126.6,115.5,115.3(d,J C-F ＝21.7Hz),50.2,49.4,17.6. 19 FNMR(376MHz,CDCl 3 )δ-112.58.。
Example 3: synthesis of 2-benzyl-5- (3, 5-dimethylphenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzyl-3- (3, 5-dimethylphenyl) propynylamide (106.0 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 74.3mg of the product in 62% yield.
The product 2-benzyl-5- (3, 5-dimethylphenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.35-7.28 (m, 5H), 7.20-7.18 (m, 2H), 7.08-7.03 (m, 2H), 6.89-6.87 (m, 3H), 5.24 (d, J=15.2 Hz, 1H), 4.55 (d, J=14.4 Hz, 1H), 4.22 (d, J=14.8 Hz, 1H), 3.97 (d, J=14.4 Hz, 1H), 2.37 (s, 3H), 2.33 (s, 6H) 13C NMR (101 MHz, CDCl 3) delta 164.2,142.2,140.4,138.7,137.9,137.0,136.8,135.1,130.9,130.1,128.8,128.2,127.9,127.9,127.7,126.5,50.2,49.3,21.4,17.6.
Example 4: synthesis of 2-benzyl-5- (4-methoxyphenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzyl-3- (4-methoxyphenyl) propynylamide (106.6 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 63.8mg of the product in 53% yield.
The product 2-benzyl-5- (4-methoxyphenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.36-7.27 (m, 5H), 7.20-7.15 (m, 4H), 7.07-7.04 (m, 1H), 6.93 (d, J=8.8 Hz, 2H), 6.88-6.85 (m, 1H), 5.21 (d, J=14.8 Hz, 1H), 4.54 (d, J=14.4 Hz, 1H), 4.21 (d, J=15.2 Hz, 1H), 3.96 (d, J=14.4 Hz, 1H), 3.84 (s, 3H), 2.35 (s, 3H) 13C NMR (101 MHz, CDCl 3) delta 164.4,159.6,141.5,138.9,137.0,137.0,134.8,132.8,131.6,131.0,128.8,128.2,127.9,127.9,127.7,126.5,113.6,55.3,50.2,49.3,17.7.
Example 5: synthesis of 4-methylsulfanyl-5-phenyl-2- (4-trifluoromethyl) benzyl) -1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N-benzyl-3-phenyl-N- (4-trifluoromethyl) benzyl propioamide (118.0 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen gas 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 68.6mg of the product in 52% yield.
Product 4-methylsulfanyl-5-phenyl-2- (4-trifluoromethyl) benzyl) -1, 2-dihydro-3H-benzo [ c ]]Azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.57 (d, J=8.0 Hz, 2H), 7.43-7.35 (m, 5H), 7.23-7.13 (m, 4H), 7.00-6.98 (m, 1H), 6.85-6.83 (m, 1H), 5.11 (d, J=15.6 Hz, 1H), 4.63 (d, J=14.4 Hz, 1H), 4.45 (d, J=15.2 Hz, 1H), 3.94 (d, J=14.4 Hz, 1H), 2.33 (s, 3H) 13C NMR (101 MHz, CDCl 3) delta 164.4,142.2,141.2,140.45,138.5,136.7,135.1,131.0,130.0,128.5,128.4,128.3,128.1,128.0 (J) C-F ＝7.1Hz)126.4,125.7,125.6(J C-F ＝3.8Hz)50.8,49.4,17.6. 19 F NMR(376MHz,CDCl 3 )δ-62.49.。
Example 6: synthesis of 2-benzyl-4-methylsulfanyl-5-m-tolyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzyl-3-m-tolylpropylamide (101.8 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube dried and repeatedly replaced with nitrogen gas 3 times at room temperature, and reacted at 80℃for 12 hours. After the reaction was completed, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 49.Mg of the product in 50% yield.
The product 2-benzyl-4-methylsulfanyl-5-m-tolyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.37-7.28 (m, 6H), 7.21-7.16 (m, 3H), 7.07-7.05 (m, 3H), 6.87-6.85 (m, 1H), 5.23 (d, J=14.8 Hz, 1H), 4.56 (d, J=14.4 Hz, 1H), 4.23 (d, J=15.2 Hz, 1H), 3.97 (d, J=14.8 Hz, 1H), 2.36 (s, 6H) 13C NMR (101 MHz, CDCl 3) delta 164.2,142.0,140.5,138.7,138.1,137.0,136.8,135.3,130.9,130.6,129.2,128.8,128.2,127.9,127.9,127.7,127.1,126.5,50.2,49.3,21.5,17.6.
Example 7: synthesis of methyl 4- (2-benzyl-4-methylsulfanyl) -3-oxo-2, 3-dihydro-1H-benzo [ c ] azepin-5-yl) benzoate
Methyl 4- (3- (dibenzylamino) -3-oxopropyl-1-yn-1-yl) benzoate (115.0 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube at room temperature, and the mixture was repeatedly replaced with nitrogen gas 3 times, and reacted at 80℃for 12 hours. After the reaction is finished, filtering and rotary steaming to obtain a crude product, and further separating and purifying by using column chromatography to obtain 60.6mg of a product with the yield of 47%; the nuclear magnetic hydrogen spectrum is shown in figure 3.
The product methyl 4- (2-benzyl-4-methylsulfanyl) -3-oxo-2, 3-dihydro-1H-benzo [ c ] azepin-5-yl) benzoate: 1HNMR (400 MHz, CDCl 3) delta 8.08 (d, J=8.4 Hz, 2H), 7.36-7.28 (m, 7H), 7.19-7.16 (m, 2H), 7.06-7.04 (m, 1H), 6.78-6.76 (m, 1H), 5.19 (d, J=15.2 Hz, 1H), 4.54 (d, J=14.4 Hz, 1H), 4.24 (d, J=14.8 Hz, 1H), 3.97 (d, J=14.4 Hz, 1H), 3.93 (s, 3H), 2.35 (s, 3H) 13C NMR (101 MHz, CDCl 3) delta 166.7,163.9,145.2,140.6,138.1,137.0,136.8,136.2,130.5,130.2,129.9,129.7,128.8,128.2,128.2,128.1,127.8,126.7,52.3,50.2,49.4,17.5. The nuclear magnetic carbon spectra are shown in FIG. 4.
Example 8: synthesis of 2- (4-fluorobenzyl) -4-methylsulfanyl-5-phenyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N-benzyl-N- (4-fluorobenzyl) -3-phenylpropyl amide (103.0 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen gas 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 53.8mg of the product in 46% yield.
Product 2- (4-fluorobenzyl) -4-methylsulfanyl-5-phenyl-1, 2-dihydro-3H-benzo [ c ]]Azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.42-7.40 (m, 3H), 7.25-7.16 (m, 6H), 7.03-6.98 (m, 3H), 6.84-6.82 (m, 1H), 5.05 (d, J=15.2 Hz, 1H), 4.56 (d, J=14.8 Hz, 1H), 4.32 (d, J=14.8 Hz, 1H), 3.95 (d, J=14.4 Hz, 1H), 2.32 (s, 3H) 13C NMR (101 MHz, CDCl 3) delta 164.2,141.9,140.5,138.6,136.9,135.3,130.9,130.0,129.9,129.9,128.42,128.4,128.0,127.9 (J) C-F ＝2.5Hz)126.4,115.7,115.5(J C-F ＝21.6Hz),50.4,48.9,17.6. 19 F NMR(376MHz,CDCl 3 )δ-114.67.。
Example 9: synthesis of 2-benzyl-5- (3-bromophenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzyl-3- (3-bromophenyl) propynylamide (121.3 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 60.8mg of the product with a yield of 45%.
The product 2-benzyl-5- (3-bromophenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.52 (d, J=7.6 Hz, 1H), 7.34-7.28 (m, 7H), 7.21-7.18 (m, 3H), 7.06-7.04 (m, 1H), 6.84-6.81 (m, 1H), 5.19 (d, J=14.8 Hz, 1H), 4.51 (d, J=14.8 Hz, 1H), 4.23 (d, J=15.2 Hz, 1H), 3.96 (d, J=14.8 Hz, 1H), 2.36 (s, 3H) 13C NMR (101 MHz, CDCl 3) delta 163.8,142.4,140.0,138.1,136.9,136.8,136.3,132.8,131.4,130.6,129.9,128.8,128.2,128.2,128.1,127.7,126.7,122.5,50.2,49.4,17.5.
Example 10: synthesis of 2-benzyl-5- (2-chlorophenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzyl-3- (2-chlorophenyl) propynylamide (108.0 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 50.0mg of the product in a yield of 41%. The nuclear magnetic hydrogen spectrum is shown in figure 5.
The product 2-benzyl-5- (2-chlorophenyl) -4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.57-7.55 (m, 1H), 7.43-7.31 (m, 8H), 7.19-7.16 (m, 2H), 7.07-7.05 (m, 1H), 6.85-6.83 (m, 1H), 5.23 (d, J=14.8 Hz, 1H), 4.67 (d, J=14.4 Hz, 1H), 4.24 (d, J=15.2 Hz, 1H), 3.98 (d, J=14.8 Hz, 1H), 2.37 (s, 3H) 13C NMR (101 MHz, CDCl 3) delta 163.6,139.5,138.7,137.0,136.9,136.8,132.6,131.6,130.3,129.8,128.8,128.6,128.2,128.0,128.0,127.7,126.7,50.2,49.5,17.3; the nuclear magnetic carbon spectrum is shown in figure 6.
Example 11: synthesis of 2-isopropyl-4-methylsulfanyl-5-phenyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N-benzyl-N-isopropyl-3-phenylpropyl amide (83.2 mg,0.30 mmol), dimethyl (methylsulfide) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlem reaction tube which was dried and repeatedly replaced with nitrogen gas 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 38.8mg of the product in 40% yield. The nuclear magnetic hydrogen spectrum is shown in figure 7.
The product 2-isopropyl-4-methylsulfanyl-5-phenyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.42-7.37 (m, 3H), 7.32-7.30 (m, 1H), 7.24-7.14 (m, 4H), 6.82-6.80 (m, 1H), 4.95-4.88 (m, 1H), 4.38 (d, J=14.8 Hz, 1H), 4.24 (d, J=14.8 Hz, 1H), 2.25 (s, 3H), 1.28 (d, J=6.8 Hz, 3H), 1.14 (d, J=6.8 Hz, 3H) 13C NMR (101 MHz, CDCl 3) delta 163.4,141.3,140.8,138.9,138.7,136.0,130.8,130.1,128.3,128.3,127.9,127.7,126.7,45.7,45.1,21.2,21.1,17.5; the nuclear magnetic carbon spectrum is shown in figure 8.
Example 12: synthesis of 4- (2-benzyl-4-methylsulfanyl) -3-oxo-2, 3-dihydro-1H-benzo [ c ] azepin-5-yl) benzonitrile
N, N-dibenzyl-3- (4-cyanophenyl) propynylamide (105.1 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen 3 times at room temperature, and reacted at 80℃for 12 hours. After the reaction is finished, filtering and rotary steaming to obtain a crude product, and further separating and purifying by using column chromatography to obtain 47.6mg of a product with the yield of 40%; the nuclear magnetic hydrogen spectrum is shown in figure 9.
The product 4- (2-benzyl-4-methylsulfanyl) -3-oxo-2, 3-dihydro-1H-benzo [ c ] azepin-5-yl) benzonitrile: 1H NMR (400 MHz, CDCl 3) delta 7.69 (d, J=8.0 Hz, 2H), 7.35-7.27 (m, 7H), 7.20-7.19 (m, 2H), 7.07-7.05 (m, 1H), 6.75-6.72 (m, 1H), 5.16 (d, J=14.8 Hz, 1H), 4.52 (d, J=14.8 Hz, 1H), 4.26 (d, J=14.8 Hz, 1H), 3.99 (d, J=14.8 Hz, 1H), 2.37 (s, 3H). 13C NMR (101 MHz, CDCl 3) delta 163.6,145.2,139.5,137.7,137.1,136.9,136.7,132.2,130.9,130.3,128.8,128.4,128.3,128.2,127.8,126.9,118.6,112.1,50.2,49.5,17.5; the nuclear magnetic carbon spectrum is shown in figure 10.
Example 13: synthesis of 2-benzyl-4-methylsulfanyl-5-thiophen-2-yl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzyl-3- (thiophen-2-yl) propylamide (99.4 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen gas 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 40.8mg of the product with a yield of 36%.
The product 2-benzyl-4-methylsulfanyl-5-thiophen-2-yl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.44 (d, J=4.8 Hz, 1H), 7.36-7.30 (m, 3H), 7.27-7.25 (m, 3H), 7.23-7.20 (m, 2H), 7.12-7.03 (m, 3H), 5.19 (d, J=14.8 Hz, 1H), 4.51 (d, J=14.8 Hz, 1H), 4.18 (d, J=15.2 Hz, 1H), 3.93 (d, J=14.4 Hz, 1H), 2.40 (s, 3H). 13C NMR (101 MHz, CDCl 3) delta 164.0,141.2,138.4,137.2,136.8,136.8,133.9,131.1,130.8,128.8,128.3,128.2,127.9,127.8,127.7,126.7,126.5,50.1,49.3,17.7.
Example 14: synthesis of 4-methylsulfanyl-5-phenyl-2-trimethylsilylmethyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one N-benzyl-3-phenyl-N- (trimethylsilyl) methylpropionamide (96.5 mg,0.30 mmol), dimethyl (methylsulfanyl) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen gas 3 times, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 37.5mg of the product in 34% yield.
The product 4-methylsulfanyl-5-phenyl-2-trimethylsilylmethyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.43-7.39 (m, 3H), 7.29-7.19 (m, 5H), 6.86 (d, J=7.8 Hz, 1H), 4.73 (d, J=14.4 Hz, 1H), 3.94 (d, J=14.4 Hz, 1H), 3.55 (d, J=15.2 Hz, 1H), 2.61 (d, J=15.2 Hz, 1H), 2.31 (s, 3H), 0.14 (s, 9H) 13C NMR (101 MHz, CDCl 3) delta 162.9,140.9,140.7,138.8,136.6,136.0,130.9,130.1,128.3,128.3,128.0,127.8,126.5,53.8,39.0,17.6, -1.40.
Example 15: synthesis of 2-benzyl-5-ethyl-4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one
N, N-dibenzylpent-2-yne (83.2 mg,0.30 mmol), dimethyl (methylthio) sulfonium triflate (93.0 mg,0.36 mmol) and acetonitrile (3 mL) were sequentially added to a 25mL Schlenk reaction tube which was dried and repeatedly replaced with nitrogen gas 3 times at room temperature, and reacted at 80℃for 12 hours. After the completion of the reaction, the crude product was obtained by filtration and rotary evaporation, and further separated and purified by column chromatography to obtain 32.0mg of the product in 33% yield.
The product 2-benzyl-5-ethyl-4-methylsulfanyl-1, 2-dihydro-3H-benzo [ c ] azepin-3-one: 1H NMR (400 MHz, CDCl 3) delta 7.46 (d, J=7.6 Hz, 1H), 7.36-7.28 (m, 4H), 7.25-7.17 (m, 3H), 7.01 (d, J=7.6 Hz, 1H), 5.16 (d, J=15.2 Hz, 1H), 4.32 (d, J=14.4 Hz, 1H), 4.12 (d, J=14.8 Hz, 1H), 3.80 (d, J=14.0 Hz, 1H), 2.97-2.79 (m, 2H), 2.45 (s, 3H), 1.11-1.08 (m, 3H) 13C NMR (101 MHz, CDCl 3) delta 164.3,144.3,137.8,137.1,133.0,128.7,128.2,127.7,127.6,127.4,126.8,50.1,49.1,28.4,17.0,13.1.
Table 1 example results table
From examples 1-15, the method of the invention is characterized in that various cheap and easily available amide compounds are reacted with commercially available sulfur salts (dimethyl (methylthio) sulfonium triflate) generated in situ by methyl triflate and dimethyl sulfide as an activating agent, and the benzoazepine compounds are obtained by reacting at 80 ℃ under the condition of nitrogen. The method has good tolerance to aryl amide compounds, alkyl amide compounds and heterocyclic amide compounds, and is a general synthesis method of the benzoazepine compounds with mild conditions and simple operation.
Example 16: optimization of the reaction System
R in the present embodiment 1 And R is 2 Are all aryl groups; under the same experimental conditions, the types of solvents, the reaction temperature and the dosage proportion are subjected to comparative experiments, and the obtained results are shown as follows:
TABLE 2 optimization of the reaction systems
Standard conditions: 1.3 mmol (1.0 eq); solvent: 3.0mL; the yield was isolated; dce=1, 2-dichloroethane, dcm=dichloromethane, mecn=acetonitrile; eq: equivalent weight; and rt: room temperature.
It should be noted that the foregoing is merely a preferred embodiment of the present invention, and is not intended to limit the scope of the present invention, and any combination or equivalent transformation made on the basis of the foregoing embodiment falls within the scope of the present invention.
Claims (9)
1. The synthesis method of the benzoazepine compound is characterized by comprising the following steps of:
wherein the activating agent is sulfur salt generated in situ by methyl triflate and dimethyl sulfide;
R 1 and R is 2 Are all substituents selected from C 1 ～C 3 Alkyl or silicon-based, 5-membered heteroaryl groups containing S heteroatoms, C 6 ～C 10 And aryl containing a secondary substituent;
the secondary substituent is selected from H, methyl, hydrocarbyloxy, ester, trifluoromethyl, isopropyl, tert-butyl, trimethylsilyl or halogen.
2. The method for synthesizing benzazepine compound according to claim 1, wherein R is as defined in the following formula 1 Preferably C 6 ～C 10 And aryl containing a secondary substituent; the secondary substituent is selected from H, methyl, hydrocarbyloxy, ester, trifluoromethyl, trimethylsilyl or halogen.
3. The method for synthesizing benzazepine compound according to claim 1, wherein R is as defined in the following formula 2 Preferably C 6 ～C 10 And containing secondary substituentsA base; the secondary substituent is selected from H, methyl, trifluoromethyl or halogen.
4. The method for synthesizing benzazepine compound according to claim 1, wherein R is as defined in the following formula 1 Preferably methyl-containing aryl, trifluoromethyl-containing aryl, F-containing aryl or trimethylsilyl; said R is 2 Aryl, F-containing aryl or trifluoromethyl-containing aryl are preferred.
5. The method for synthesizing the benzazepine compound according to claim 1, wherein the molar ratio of the dimethyl (methylthio) sulfonium triflate to the amide compound is 1-1.5:1.
6. The method for synthesizing a benzazepine compound according to claim 6, wherein the molar ratio of dimethyl (methylthio) sulfonium triflate to amide compound is 1.2:1.
7. The method for synthesizing the benzazepine compound according to claim 6, wherein the reaction solvent is acetonitrile; the molar concentration of the amide compound in the reaction solvent is 0.1mmol/mL.
8. The method for synthesizing the benzazepine compound according to claim 1, wherein the reaction temperature of the method is 20-90 ℃, preferably 80 ℃; the reaction time is 8 to 18 hours, preferably 12 hours.
9. The method for synthesizing the benzoazepine compound according to claim 1, wherein the method is characterized in that after the reaction is completed, the benzoazepine compound is obtained after being refined by column chromatography separation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310148318.3A CN116396218A (en) | 2023-02-22 | 2023-02-22 | Synthesis method of benzazepine compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310148318.3A CN116396218A (en) | 2023-02-22 | 2023-02-22 | Synthesis method of benzazepine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116396218A true CN116396218A (en) | 2023-07-07 |
Family
ID=87014937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310148318.3A Pending CN116396218A (en) | 2023-02-22 | 2023-02-22 | Synthesis method of benzazepine compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116396218A (en) |
-
2023
- 2023-02-22 CN CN202310148318.3A patent/CN116396218A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109912606B (en) | Synthesis method of pyrimido indazole compound | |
| Ye et al. | Synthesis of 2-aminopyridines via ruthenium-catalyzed [2+ 2+ 2] cycloaddition of 1, 6-and 1, 7-diynes with cyanamides: scope and limitations | |
| IE57057B1 (en) | Carboxamides,process for their preparation and pharmaceutical preparations containing them | |
| EP0496692A1 (en) | 2-Methoxyphenylpiperazine derivatives | |
| Xia et al. | One-pot asymmetric synthesis of a spiro [dihydrofurocoumarin/pyrazolone] scaffold by a Michael addition/I 2-mediated cyclization sequence | |
| CN108863890B (en) | 4-pyrroline-2-ketone derivative and preparation method thereof | |
| CN116396218A (en) | Synthesis method of benzazepine compound | |
| CN114874139B (en) | Synthesis method of 1-benzyl or allyl 3, 4-dihydroisoquinoline | |
| CN108610275A (en) | A kind of synthetic method of 3- (2- vinyls) indole derivatives | |
| CN114195792B (en) | Synthesis method of 1,2, 3-triazole quinoxalinone derivative | |
| IL90533A (en) | 5-phenyl-8-nitro-2,3,4,5-tetrahydro-1h-3- benzazepine derivatives, their preparation and pharmaceutical compositions containing them | |
| KR20230023566A (en) | one-pot synthesis Method of 1,3-Disubstitued indolizines | |
| JP4157766B2 (en) | Process for producing substituted imidazopyridine compounds | |
| US20040110944A1 (en) | 4,7-Disubstituted indoles and methods of making | |
| KR101637177B1 (en) | Process for preparing 8-hydroxyclomipramine or its pharmaceutically acceptable salt | |
| CN106083649B (en) | A kind of synthetic method of the Cyclohexadiene derivatives of 3,5 diaryl, 2,6,6 tricyano, 1 imino group 2,4 | |
| CN114920616B (en) | Synthesis process of amidine compound | |
| Shumaila et al. | Diastereoselective synthesis of 1, 1, 4-trisubstituted-2, 3, 4, 9-tetrahydrospiro-β-carbolines via glacial acetic acid catalyzed Pictet-Spengler reaction | |
| CN110804007B (en) | Polysubstituted pyrrole derivative and preparation method thereof | |
| CN110041355B (en) | Method for synthesizing boron-substituted chiral dibenzo-1, 4-aza compounds | |
| CN116082336A (en) | Preparation method for synthesizing multifunctional indolizine derivative by copper catalysis | |
| CN111808045B (en) | Method for synthesizing chiral seven-element cyclic sulfonamide through organic catalysis | |
| Zhang et al. | Transition-metal-free, mild and efficient ring expansion of amino acid derivatives: facile access to densely functionalized azepines | |
| CN116120229A (en) | Preparation method of polysubstituted 1,2,3, 4-tetrahydroquinoline | |
| Bhuyan et al. | tert-Butylhydroperoxide mediated radical cyanoalkylation/cyanoalkenylation of 2-anilino-1, 4-naphthoquinones with vinylarenes/arylalkynes and azobis (alkylcarbonitrile) s |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |